Kazuaki Harada

7PUBLICATIONS
26CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Apr 13, 2026
Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).

Yusuke Sano, Masato Ozaka, Shuichi Aoki

|Mar 28, 2026
High CD73 Expression Is Associated with Poor Prognosis in Biliary Tract Cancer Through Reduced Stromal Tumor-Infiltrating Lymphocytes.

Shoya Shiratori, Kazumichi Kawakubo, Kanako C Hatanaka

|Jul 29, 2025
Urinary Titin as a Non-Invasive Biomarker for Sarcopenia Sex Differences in Unresectable Digestive Malignancies: A Retrospective Cohort Study.

Shiho Kaneko, Kazuaki Harada, Masatsugu Ohara

|Nov 30, 2023
Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases.

Kazuaki Harada, Satoshi Yuki, Yasuyuki Kawamoto

|May 17, 2022
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.

Yasuyuki Kawamoto, Satoshi Yuki, Kentaro Sawada

|May 29, 2021
A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403).

Yasuyuki Kawamoto, Hiroshi Nakatsumi, Kazuaki Harada

Pageof 2

Frequent Collaborators

4 joint publications

Yasuyuki Kawamoto

3 joint publications

Satoshi Yuki

2 joint publications

Yoshito Komatsu

1 joint publications

Michio Nakamura